David Moatazedi is recorded as CFO at Evolus, Inc. (EOLS) since August 1, 2025, Board Member at Evolus, Inc. (EOLS) since June 6, 2024 and CEO at Evolus, Inc. (EOLS). David Moatazedi was last confirmed as Board Member at Biomerica Inc (BMRA) in a filing dated October 20, 2025. Evolus, Inc. reported in an 8-K filed August 5, 2025 that David Moatazedi was appointed Principal Financial Officer, effective August 1, 2025. Evolus, Inc. reported in an 8-K filed June 11, 2024 that David Moatazedi was appointed Class III Director, effective June 6, 2024. Biomerica Inc reported in an 8-K filed December 9, 2022 that David Moatazedi was appointed member of the Board of Directors, effective December 7, 2022. The proxy statement of Evolus, Inc. reports total compensation of $6,412,214 for David Moatazedi in fiscal 2025, including a base salary of $775,000. Disclosed compensation is on record for 8 fiscal years. David Moatazedi has spoken on 25 earnings calls and 1 other investor event across 1 company, most recently for Evolus, Inc. on August 5, 2026. Evolus, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Evolus, Inc. includes Albert G. White III (Board Member), Albert White III (Board Member), Brady Stewart (Board Member) and 3 others.
“On August 1, 2025, the Company's Board of Directors appointed David Moatazedi, the Company's President and Chief Executive Officer, to serve as Principal Financial Officer of the Company until a new Principal Financial Officer is appointed.”
Evolus, Inc. Form 8-K, filed August 5, 2025
· Read the filing
“The stockholders of the Company elected each of David Moatazedi, Vikram Malik and Karah Parschauer as Class III Directors for a three-year term ending at the Annual Meeting of Stockholders to be held in 2027 and until each of their successors has been duly elected and qualified, or until their earlier death, resignation or removal.”
Evolus, Inc. Form 8-K, filed June 11, 2024
· Read the filing
David Moatazedi on recent calls
“The second quarter represents a meaningful inflection point for Evalus.”
“It's our first time attending the Jefferies Conference, and it's great to be here. You're right. The company looks very different over the last 24 months.”
“We started 2026 with strong momentum that carried over from the fourth quarter, resulting in our second consecutive quarter of positive adjusted EBITDA. Importantly, we achieved this in what is seasonally our lowest revenue quarter of the year and against our strongest prior year comparison.”
“Before reviewing our 2025 performance and outlining our objectives for 2026, I would like to take a step back and provide a broader perspective around our performance beauty strategy.”
“Before we begin, I'd like to take a moment to welcome Tatjana Mitchell as our new Chief Financial Officer. Tatjana brings deep financial and operational expertise to Evolus, and she's made an immediate impact as we strengthen our focus on efficiency and long-term growth.”
